Innovative Practice in Breast Health最新文献

Bosutinib: Transforming the therapeutic landscape for HER2-positive and triple-negative breast cancer 博舒替尼：改变her2阳性和三阴性乳腺癌的治疗前景

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100042

Rishabh Agade, Ujban Hussain, Aditya R. Wadalkar, Abhijeet A. Chalkhor, Prashant K. Puranik, Veena Belgamwar

{"title":"Bosutinib: Transforming the therapeutic landscape for HER2-positive and triple-negative breast cancer","authors":"Rishabh Agade, Ujban Hussain, Aditya R. Wadalkar, Abhijeet A. Chalkhor, Prashant K. Puranik, Veena Belgamwar","doi":"10.1016/j.ibreh.2025.100042","DOIUrl":"10.1016/j.ibreh.2025.100042","url":null,"abstract":"<div><div>Breast cancer remains one of the most prevalent and challenging malignancies, especially in aggressive subtypes such as HER2-positive and triple-negative breast cancer (TNBC). These subtypes are characterized by rapid proliferation, high metastatic potential, and resistance to conventional therapies, leading to poor prognosis. Bosutinib, a second-generation tyrosine kinase inhibitor, has emerged as a promising therapeutic candidate due to its dual inhibition of SRC family and Abl kinases, which are pivotal in cancer cell proliferation, survival, and metastasis. Preclinical and clinical studies indicate that bosutinib effectively suppresses tumor growth, induces apoptosis, and reduces metastatic potential. Moreover, its combination with existing therapies, such as trastuzumab or immune checkpoint inhibitors, enhances therapeutic efficacy, particularly in resistant cases. Innovative strategies, including nanoparticle-based delivery systems, further improve bosutinib’s bioavailability and targeted action, minimizing systemic toxicity. However, challenges such as resistance development and toxicity management require ongoing investigation. This review underscores bosutinib’s potential in addressing therapeutic resistance and highlights its role in precision medicine, advancing breast cancer treatment.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic excision results in benign and borderline breast lesions by the breast lesion excision system (BLES) 乳腺病变切除系统（BLES）对乳腺良性和交界性病变进行治疗性切除。

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100043

Mirsad Yalcinkaya , Mehmet Ali Nazlı , Canan Kelten Talu , Gultekin Ozan Kucuk , Ozgur Kılıckesmez

{"title":"Therapeutic excision results in benign and borderline breast lesions by the breast lesion excision system (BLES)","authors":"Mirsad Yalcinkaya , Mehmet Ali Nazlı , Canan Kelten Talu , Gultekin Ozan Kucuk , Ozgur Kılıckesmez","doi":"10.1016/j.ibreh.2025.100043","DOIUrl":"10.1016/j.ibreh.2025.100043","url":null,"abstract":"<div><h3>Background</h3><div>Breast lesion excision system (BLES) is an alternative biopsy method that allows large specimens to be received from the tissue.</div></div><div><h3>Objectives</h3><div>This study aims to evaluate the therapeutic results of the biopsies performed breast lesions using the BLES.</div></div><div><h3>Methods</h3><div>The study included 23 patients who underwent biopsy with the BLES between January 2014 and December 2016. All of the relevant procedures were performed under local anesthesia. After the procedure, the excision site was closely observed using ultrasonography and analyzed for macroscopic residual lesions. All specimens were evaluated using the diagnostic or therapeutic accuracy or safety of BLES.</div></div><div><h3>Results</h3><div>The mean lesion size was 11.3 ± 4.4 mm. The size was ≤10 mm in 11 patients, and between 10 mm and 20 mm in 12 patients. Pathologic evaluation could not be performed in 1 patient due to an empty basket. According to the first BLES procedure, in the patient group with a target lesion size ≤10 mm, complete removal was achieved in 9 patients (90.0 %) and incomplete removal in 1 patient (10.0 %). In the patient group with a target lesion size between 10 mm and 20 mm, complete removal was achieved in 5 patients (42 %) and incomplete removal in 7 patients (58 %) (<em>p</em> = 0.019). No complications such as bleeding, hematoma, or infection were detected in our study.</div></div><div><h3>Conclusion</h3><div>BLES is a minimally invasive, safe and effective alternative to surgical excision, especially in suitable sizes, as it does not require general anesthesia and can be done as an outpatient procedure.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the potential of CRISPR in triple-negative breast cancer treatment 探索CRISPR在三阴性乳腺癌治疗中的潜力

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2024.100028

Lopamudra Chakravarty , Sk Imtiaz Ahmad , Afsona Khatun , Sahabaj Ali Khan

{"title":"Exploring the potential of CRISPR in triple-negative breast cancer treatment","authors":"Lopamudra Chakravarty , Sk Imtiaz Ahmad , Afsona Khatun , Sahabaj Ali Khan","doi":"10.1016/j.ibreh.2024.100028","DOIUrl":"10.1016/j.ibreh.2024.100028","url":null,"abstract":"<div><div>The CRISPR/Cas9 gene editing system, derived from prokaryotic adaptive defense mechanisms, has revolutionized various fields by enabling precise gene editing. Its impact has been particularly significant in cancer research, facilitating improved disease modeling, identification of new cancer-related genes, and more accurate diagnosis, especially for challenging subtypes like triple-negative breast cancer (TNBC). TNBC's resistance to targeted therapies due to the absence of hormone receptors underscores the importance of CRISPR technology. Utilizing guide RNA to direct Cas9 enzyme to specific genomic loci, the CRISPR system induces double-strand breaks, which are repaired by endogenous DNA repair mechanisms, enabling gene insertions, deletions, or modifications. The CRISPR process involves three key steps: guide RNA design and complex formation with Cas9, DNA cleavage at the target site, and cellular repair through non-homologous end joining or homology-directed repair pathways. With its versatility and precision, CRISPR/Cas9 emerges as a potent tool driving innovative cancer research and therapeutic development.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100028"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genome medicine and breast cancer in Africa 基因组医学和非洲的乳腺癌

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100040

Abdullahi Tunde Aborode , Soyemi Toluwalashe , Ibrahim O. Adelakun , Segun Olapade , Segun E. Ogungbemi , Boluwatife T. Dosunmu , Isreal Ayobami Onifade , Ridwan Olamilekan Adesola , Adetolase Azizat Bakre , Godfred Yawson Scott

引用次数: 0

Endoscopic mastectomy: quick and fast in 5 steps 内窥镜乳房切除术：快速快速5步

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100039

G. Rathat , C. Vaysse

引用次数: 0

Breast cancer detection redefined: Integrating Xception and EfficientNet-B5 for superior mammography imaging 重新定义乳腺癌检测：整合Xception和EfficientNet-B5，实现卓越的乳房x线摄影成像

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100038

Niha Talukdar , Anchita Kakati , Upasana Barman , Jyoti Prakash Medhi , Kandarpa Kumar Sarma , Geetanjali Barman , Binoy Kumar Choudhury

{"title":"Breast cancer detection redefined: Integrating Xception and EfficientNet-B5 for superior mammography imaging","authors":"Niha Talukdar , Anchita Kakati , Upasana Barman , Jyoti Prakash Medhi , Kandarpa Kumar Sarma , Geetanjali Barman , Binoy Kumar Choudhury","doi":"10.1016/j.ibreh.2025.100038","DOIUrl":"10.1016/j.ibreh.2025.100038","url":null,"abstract":"<div><h3>Background and Objective:</h3><div>Breast cancer is a major cause of female mortality, with early detection crucial for effective treatment. This study aims to enhance mammographic breast cancer detection by integrating an autoencoder’s encoder unit with advanced Convolutional Neural Networks (CNNs), incorporating soft attention gates and feature merging for improved accuracy. A custom multi-head attention mechanism is utilized for precise tumor segmentation, with a focus on robust validation across diverse datasets.</div></div><div><h3>Methods:</h3><div>The research involved 3816 mammogram samples (2376 benign, 1440 malignant) and employed deep learning techniques combining model fusion and autoencoders for classification. A custom multi-head attention mechanism was applied for tumor segmentation. The models were validated on publicly available datasets, MIAS and CBIS-DDSM.</div></div><div><h3>Results:</h3><div>On the MIAS dataset, Xception and EfficientNet-B5 CNN models outperformed others, achieving a classification accuracy of 96.88% after autoencoder integration. For segmentation, the model demonstrated strong alignment with tumor regions, achieving a Dice Coefficient of 0.4353, Intersection over Union (IoU) of 0.2998, and F1-Score of 0.4318.</div></div><div><h3>Conclusion:</h3><div>This study developed a robust deep learning approach combining Xception and EfficientNet-B5 for breast cancer diagnosis and segmentation. The fused model demonstrated high classification accuracy and reliable segmentation performance, indicating strong potential for clinical applications in early breast cancer detection and treatment planning.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144491582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

History of breast reconstruction : Towards the era of endoscopic mastectomy ? 乳房重建的历史：走向内窥镜乳房切除术时代？

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100035

Gauthier Rathat, Martha Duraes

引用次数: 0

Proposed French recommendations for breast cancer screening in the trans population 法国对跨性别人群乳腺癌筛查的建议

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100041

Susie Brousse , Marie-Catherine Morin-Charbonnier , Sophie Guillermet , Maïté Briet , Sophie Harter , Céline Lescure , Louise Crivelli , Jeanne Lemerre-Poincloux , Bernadette Leproust , Marine Tas , Ariane Weyl , Lucas Freton

{"title":"Proposed French recommendations for breast cancer screening in the trans population","authors":"Susie Brousse , Marie-Catherine Morin-Charbonnier , Sophie Guillermet , Maïté Briet , Sophie Harter , Céline Lescure , Louise Crivelli , Jeanne Lemerre-Poincloux , Bernadette Leproust , Marine Tas , Ariane Weyl , Lucas Freton","doi":"10.1016/j.ibreh.2025.100041","DOIUrl":"10.1016/j.ibreh.2025.100041","url":null,"abstract":"<div><h3>Introduction</h3><div>Transgender patients are increasingly able to assert their gender identity. Nevertheless, their access to care is still limited, mainly due to poorly trained and informed healthcare professionals. Because of a growing incidence of breast cancer (BC) and insufficient screening in France, it is vital to improve access for trans people. Therefore, we aim to produce the first French recommendations adapted to them.</div></div><div><h3>Materials and methods</h3><div>This work is based on the recommendations of the WPATH, the ACR, and a review of the literature.</div></div><div><h3>Results</h3><div>First, there is no excess risk of BC in the trans population. The risk for trans women is 0.3 times that of <em>cis</em> women, 47 times that of <em>cis</em> men, and twice that of trans men. The risk for trans men is 59 times that of <em>cis</em> men, and 0.2 times that of <em>cis</em> women (reduced by the use of testosterone and torsoplasty). The recommendations for BC screening are thus the same for trans men without torsoplasty, and for trans women after 5 years of gender-affirming hormone therapy, as for <em>cis</em> women. These should be adapted to the personal and family histories.</div></div><div><h3>Discussion</h3><div>The lack of inclusion of trans patients in studies makes it impossible to give recommendations that differ from those for <em>cis</em> women. The training of healthcare professionals and the provision of information to patients are vital to the screening and prevention of BC, which are mainly hormone-dependent, thus often contraindicating the gender-affirming hormone therapy essential for trans patients afterwards.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of the literature: Mammography positioning, body habitus (thorax) and image evaluation system 文献综述：乳房x线摄影定位，身体体质（胸部）和图像评价系统

Innovative Practice in Breast Health Pub Date : 2025-01-01 DOI: 10.1016/j.ibreh.2025.100034

Ruth Pape , Caryn West

{"title":"A review of the literature: Mammography positioning, body habitus (thorax) and image evaluation system","authors":"Ruth Pape , Caryn West","doi":"10.1016/j.ibreh.2025.100034","DOIUrl":"10.1016/j.ibreh.2025.100034","url":null,"abstract":"<div><div>The early detection of breast cancer using mammography relies on optimal positioning of the craniocaudal (CC) and the mediolateral oblique (MLO) views to include as much of the breast as possible; and subsequent assessment of image quality using valid image evaluation systems (IES). This review highlights the key positioning literature and IES; and discusses the fundamental issues impacting best practice positioning including body habitus, specifically the thorax. Due to variations in the shape of the thorax and the impact of the linear image receptor (IR) on positioning, the inclusion of all breast tissue may not be possible. Further, body habitus, including the shape of the thorax, is not reflected in any IES. Although used worldwide the lack of consideration given to individual body habitus is a key deficit of all IES. There is no mention in the literature of how to manage thoracic variability to maximise breast tissue inclusion outside of the selection of the angle of the IR in the MLO view. No known studies have investigated the degree to which the oppositional curvilinear thorax and the linear mammography IR impact the amount of breast able to be included in the image. Both issues support the need for future research.</div></div>","PeriodicalId":100675,"journal":{"name":"Innovative Practice in Breast Health","volume":"7 ","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143512138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ours 我们的

Innovative Practice in Breast Health Pub Date : 2024-12-01 DOI: 10.1016/S2950-2128(24)00031-9

引用次数: 0